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ABSTRACT

Objective: To compare the neuroimaging profile and clinical outcomes among patients with intracerebral hemorrhage (ICH) related to use of vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF).

Methods: We evaluated consecutive patients with NVAF with nontraumatic, anticoagulantrelated ICH admitted at 13 tertiary stroke care centers over a 12-month period. We also performed a systematic review and meta-analysis of eligible observational studies reporting baseline
characteristics and outcomes among patients with VKA- or DOAC-related ICH.
Results: We prospectively evaluated 161 patients with anticoagulation-related ICH (mean age 75.6 6
9.8 years, 57.8% men, median admission NIH Stroke Scale [NIHSSadm] score 13 points, interquartile
range 6–21). DOAC-related (n 5 47) and VKA-related (n 5 114) ICH did not differ in demographics,
vascular risk factors, HAS-BLED and CHA2DS2-VASc scores, and antiplatelet pretreatment except
for a higher prevalence of chronic kidney disease in VKA-related ICH. Patients with DOAC-related ICH
had lower median NIHSSadm scores (8 [3–14] vs 15 [7–25] points, p 5 0.003), median baseline
hematoma volume (12.8 [4–40] vs 24.3 [11–58.8] cm3, p 5 0.007), and median ICH score (1 [0–2]
vs 2 [1–3] points, p 5 0.049). Severe ICH (.2 points) was less prevalent in DOAC-related ICH (17.0%
vs 36.8%, p 5 0.013). In multivariable analyses, DOAC-related ICH was independently associated
with lower baseline hematoma volume (p 5 0.006), lower NIHSSadm scores (p 5 0.022), and lower
likelihood of severe ICH (odds ratio [OR] 0.34, 95% confidence interval [CI] 0.13–0.87, p 5 0.025). In
meta-analysis of eligible studies, DOAC-related ICH was associated with lower baseline hematoma
volumes on admission CT (standardized mean difference 5 20.57, 95% CI 21.02 to 20.12, p 5
0.010) and lower in-hospital mortality rates (OR 5 0.44, 95% CI 0.21–0.91, p 5 0.030).
Conclusions: DOAC-related ICH is associated with smaller baseline hematoma volume and lesser neurologic deficit at hospital admission compared to VKA-related ICH. Neurology® 2017;89:1142–1151
GLOSSARY
CI 5 confidence interval; CMB 5 cerebral microbleed; CMB-NOW 5 Cerebral Microbleeds During the Non-Vitamin K Antagonist
Oral Anticoagulants or Warfarin Therapy in Stroke Patients With Nonvalvular Atrial Fibrillation; DOAC 5 direct oral anticoagulant;
ICH 5 intracranial hemorrhage; INR 5 international normalized ratio; IQR 5 interquartile range; MOOSE 5 Meta-Analysis of
Observational Studies Epidemiology; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke Scale; NVAF 5 nonvalvular atrial fibrillation; OR 5 odds ratio; PRISMA 5 Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RE-LY 5 Randomized
Evaluation of Long-Term Anticoagulation Therapy; ROCKET AF 5 Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; VKA 5 vitamin K antagonist.

Oral anticoagulation prevents thromboembolism and significantly reduces mortality in patients
with nonvalvular atrial fibrillation (NVAF).1 The most feared complication related to the use of
oral anticoagulation is intracranial hemorrhage (ICH), which has been associated with a higher
From the Department of Neurology (G.T., N.G., A.K., J.C., A.W.A., A.V.A.), University of Tennessee Health Science Center, Memphis; Second
Department of Neurology (G.T., A.H.K., C.Z., S.T., M.I., A.B.), “Attikon” Hospital, School of Medicine, National and Kapodistrian University of Athens,
Greece; Department of Neurology (V.-A.L., C.N.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Neurology
(P.V., C.M., M.J., P.M.), Henry Ford Hospital, Detroit, MI; Department of Neurology (A.H.K., S.G.), University of Ioannina School of Medicine, Greece;
International Clinical Research Center (R.M.), Neurology Department, St. Anne’s Hospital and Masaryk University, Brno, Czech Republic; Department of
Neurology (K.B.), Dresden University Stroke Center; Department of Neurology (C.K., C.S.), St. Josef-Hospital, Ruhr University of Bochum, Germany;
Division of Neurology (V.K.S.), Yong Loo Lin School of Medicine, National University of Singapore; Department of Neurology (K.V.), Democritus
University of Thrace, Alexandroupolis, Greece; Department of Neurology (E.D., A.P.), University of Thessaly, Larissa; Second Department of Neurology
(T.K.), AHEPA University Hospital, Aristotelian University of Thessaloniki; Acute Stroke Unit (O.K.), Metropolitan Hospital, Piraeus; Laboratory of
Haematology and Blood Bank Unit (A.T.), “Attikon” Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece; Australian
Catholic University (A.W.A.), School of Nursing, Sydney, Australia; and Department of Neurology (P.M.), University of Crete, Heraklion, Greece.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
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likelihood of both hematoma expansion and
mortality.2 Even though direct oral anticoagulants (DOACs) have shown to be both safe
and effective for ischemic stroke prevention
in patients with NVAF3,4 with half the risk
for ICH compared to vitamin K antagonists
(VKAs),5,6 preliminary findings of a recent
multicenter registry indicate that DOACrelated ICHs also carry a high risk for both
hematoma expansion and unfavorable clinical
outcomes.7 The concern regarding both hematoma expansion and subsequent worse outcomes in DOAC-related ICHs is exacerbated
by the lack of approved specific antidotes for
DOACs (except for dabigatran) compared to
VKAs.8
In view of the former considerations, we
sought to compare the neuroimaging profiles
and clinical outcomes between DOAC- and
VKA-related nontraumatic ICHs in a prospective, multicenter, cross-sectional study. Given
the scarce available data comparing neuroimaging and clinical outcomes between
DOAC- and VKA-related ICH, we also performed a systematic review and meta-analysis
to summarize all available literature data and
to further evaluate the association of DOAC(vs VKA-) related ICH with radiologic and
clinical outcome measures.
METHODS Multicenter study population and methods.
We prospectively enrolled consecutive patients with nontraumatic ICH and positive history of oral anticoagulant intake
who presented in the emergency rooms of the participating tertiary care stroke centers during a 1-year period (June 2015–July
2016). More specifically, the definition of VKA-related ICH
required effective use of VKA with an international normalized
ratio (INR) of .1.5 on hospital admission as previously
described.9 Patients with major head trauma or known underlying structural or vascular cause of ICH were excluded from further evaluation. We also excluded patients with cerebral ischemia
and hemorrhagic transformation. Details of the complete list of
participating institutions, the parameters that were recorded, and
the statistical analysis are available in the supplemental material at
Neurology.org.10
Noncontrast head CT scans were performed for all patients
both at baseline and within 24 hour after ictus. CT findings were
interpreted and extracted independently by either neurologists or
neuroradiologists in each participating institution who were
unaware of each patient’s clinical data. Hematoma volume in
both baseline and follow-up (within the first 24 hours) CT scans
was calculated from the slices of CT images in each patient with
the ABC/2 method,11 while expansion of hematoma at 24 hours
was defined as an absolute increase of .12.5 mL or a relative
increase of .33% in hematoma volume at the 24-hour CT scan
compared to the admission CT scan.12 Repeat CT scans were also
systematically evaluated and compared with the admission CT

scan for the presence of edema or midline shift within the first 24
hours from the index event.
For each included patient, we additionally calculated the corresponding body mass index score, creatinine clearance on admission
estimated by the Cockcroft-Gault equation, CHA2DS2-VASc
score,13 HAS-BLED score,14 and ICH score.15 Severe ICH on
admission was defined as an index event with an ICH score of
.2. This specific cutoff was selected because in the original cohort
an ICH score of .2 was associated with a significant increase in
30-day mortality (72% vs 26%).15
In the participating centers, all eligible patients were treated according to current guidelines for the management of
spontaneous ICH.16 Intubation, surgical decompression, or
external ventricular drainage was indicated by case on the basis
of both neurologic deterioration and findings on the repeat CT
scan. NIH Stroke Scale (NIHSS) score at 24 hours and hospital discharge and modified Rankin Scale (mRS) scores at
both discharge and 3 months were obtained as standard of care
for all patients. Disability at 3 months was defined as an mRS
score of .2.12

Standard protocol approvals, registrations, and patient
consents. The study was approved by the corresponding institutional ethical standards committees in each participating center,
and written informed consent was obtained from all patients or
guardians.

Search strategy and data extraction from previous studies.
The meta-analysis has adopted the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines for
systematic reviews and meta-analyses17 and was written according
to the Meta-Analysis of Observational Studies Epidemiology
(MOOSE) proposal.18 Eligible observational studies reporting
baseline characteristics and outcomes among patients with VKArelated or DOAC-related ICH were identified by searching
MEDLINE and SCOPUS.
In each study that met the inclusion criteria, for the quantitative analysis, the Newcastle-Ottawa Scale for assessing the quality of nonrandomized studies in meta-analyses tool was used.19
Quality control and bias identification were performed independently by 3 reviewers (G.T., A.H.K., and A.V.A.), and all emerging conflicts were resolved with consensus. For each included
study, the numbers of events in patients with VKA-related or
DOAC-related ICH were identified, and the corresponding odds
ratios (ORs) were calculated. For studies with a zero cell, we used
a continuity correction of 0.5 as appropriate. Continuous outcomes were pooled as standardized mean differences, calculated as
the mean differences divided by the corresponding pooled SDs.
Further details on the meta-analysis protocol are available in the
supplemental material.

Statistical analyses. Multicenter cross-sectional study. Statistical comparisons between different subgroups were performed
with appropriate tests. The distribution of the 3-month mRS
scores among groups was compared with the Cochran-MantelHaenszel test and univariable/multivariable ordinal logistic
regression (shift analysis).20
Univariable and multivariable regression analyses were also
used to evaluate the associations between baseline characteristics
and outcomes of interest. In all linear regression analyses, baseline
hematoma volume and admission NIHSS (NIHSSadm) score
were cube root and log transformed, respectively, to satisfy statistical assumptions regarding normality of the distribution.21,22
We reported all associations as linear regression coefficients in
linear regression models, ORs in logistic regression models, and
common ORs in ordinal regression models.
Neurology 89

September 12, 2017

1143

ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

Table 1

Baseline characteristics of patients pretreated with DOACs and VKAs
DOACs (n 5 47)

Variable

VKAs (n 5 114)

p Value

Baseline clinical characteristics
Age, mean 6 SD, y

76.6 6 9.5

75.2 6 9.9

0.417

Male, %

57.4

57.9

0.958

BMI, mean 6 SD, kg/m2

27.0 6 5.5

28.4 6 6.6

0.248

White

87.2

72.8

Black

6.4

16.7

Asian

6.4

8.8

Hispanic

Race, %

0

1.7

CHA2DS2-VASc score, mean 6 SD

4.5 6 1.8

4.4 6 1.6

0.771

HAS-BLED score, mean 6 SD

2.7 6 1.0

2.9 6 1.1

0.143

Hypertension, %

95.7

93.8

0.636

Diabetes mellitus, %

44.7

41.2

0.687

Hyperlipidemia, %

51.1

57.9

0.427

Heart failure, %

21.3

24.6

0.655

Current smoking, %

6.4

11.4

0.333

Coronary artery disease, %

23.4

39.5

0.052

Chronic kidney disease, %

6.5

21.9

0.020

History of any stroke, %

39.5

38.3

0.889

History of ischemic stroke, %

38.3

37.7

0.945

History of ICH, %

6.4

6.1

0.954

Statin pretreatment, %

47.7

59.1

0.199

Antiplatelet pretreatment, %

27.3

38.5

0.187

Dual antiplatelet pretreatment, %

2.3

7.3

0.231

Dabigatran

8 (17)

—

—

Rivaroxaban

24 (51)

Apixaban

15 (32)
15 (7–25)

0.003

DOAC type, n (%)

NIHSS score at admission, median (IQR)

8 (3–14)

GCS score at admission, median (IQR)

14 (12–15)

13 (7–15)

0.008

SBP admission, mean 6 SD, mm Hg

175.1 6 31.9

172.5 6 32.1

0.639

DBP admission, mean 6 SD, mm Hg

94.4 6 20.4

91.4 6 18.5

0.377

1.6 6 0.72

2.9 6 1.14

,0.001

34.8 6 6.1

40.3 6 11.2

0.002

Platelet count, median (IQR), n 3 10 /mL

195 (172–233)

206 (166–256)

0.635

CrCl on admission, mean 6 SD, mL/min

66.4 6 18.4

66.5 6 34.1

0.980

Lobar hemorrhage, %

44.7

58.8

0.102

Intraventricular hemorrhage, %

36.2

43.0

0.424

Baseline ICH volume, median (IQR), cm3

12.8 (4–40)

24.3 (11–58.8)

0.007

Baseline ICH volume >30 cm , %

25.5

45.6

0.018

Baseline laboratory values
INR at admission, mean 6 SD
aPTT at admission, mean 6 SD, s
3

Baseline CT findings

3

Continued
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Table 1

Continued
DOACs (n 5 47)

VKAs (n 5 114)

p Value

ICH score, median (IQR)

1 (0–2)

2 (1–3)

0.049

Severe ICH, %a

17.0

36.8

0.013

Variable

Abbreviations: aPTT 5 activated partial thromboplastin time; BMI 5 body mass index; CrCl 5 creatinine clearance; DBP 5
diastolic blood pressure; DOAC 5 direct oral anticoagulant; GCS 5 Glasgow Coma Scale; ICH 5 intracerebral hemorrhage;
INR 5 international normalized ratio; IQR 5 interquartile range; NIHSS 5 NIH Stroke Scale; SBP 5 systolic blood pressure;
VKA 5 vitamin K antagonist.
a
Defined as an ICH score of .2.

RESULTS Multicenter cross-sectional study. A total of
161 consecutive patients with ICH (mean age 75.6
6 9.8 years, 57.8% men, median NIHSSadm score
13 points, interquartile range [IQR] 6–21) were
admitted in the 13 participating institutions during
the 1-year period with DOAC-related (n 5 47) and
VKA-related (n 5 114) ICH. The 47 patients with

Table 2

DOAC-related ICH were pretreated with dabigatran (n 5 8), rivaroxaban (n 5 24), and apixaban
(n 5 15).
Patients with VKA- and DOAC-related ICH did
not differ in demographics, HAS-BLED and
CHA2DS2-VASc scores, antithrombotic medications, or vascular risk factors, except for a higher

Clinical and radiologic outcomes of patients with ICH pretreated with DOACs and VKAs
DOACs (n 5 47)

VKAs (n 5 114)

p Value

FFP

6.4

27.2

0.003

PCC

34.0

59.6

0.003

Vitamin K

10.8

71.9

,0.001

Idarucizumab

2.2

—

—

Surgical decompression

6.3

7.9

0.740

External ventricular drainage

14.9

15.8

0.887

Intubation

23.4

32.4

0.254

Variable
Therapies/interventions, %

Radiologic outcomes at 24 h
ICH volume at 24 h, cm3 median (IQR)

19.8 (6.9–43.6)

28.4 (12.6–56)

0.217

ICH volume >30 cm3 at 24 h, %

42.5

56.1

0.117

Absolute ICH growth at 24 h, median (IQR)

1.12 (20.83 to 5.6)

2.6 (21.73 to 15)

0.347

Hematoma expansion, %

23.1

37.1

0.116

Cerebral edema, %

53.2

71.0

0.030

Midline shift, %

26.1

45.6

0.022

NIHSS score at 24 h, median (IQR)

6 (2–15)

15 (6–23)

0.007

Absolute NIHSS decrease at 24 h, median (IQR)

0 (21 to 1)

0 (22 to 0)

0.274

Days of hospitalization, median (IQR)

8 (4–17)

8.5 (4–14)

0.446

NIHSS score at discharge, median (IQR)

3 (1–10)

6 (3.5–15)

0.011

mRS score at discharge, median (IQR)

3 (1–5)

4 (3–6)

0.002

In-hospital mortality, %

21.2

33.3

0.128

mRS score at 3 mo, median (IQR)

3 (0–5)

4 (3–6)

0.001

Disability at 3 mo,a %b

51.1

76.3

0.002

21.7

36.3

0.075

Clinical outcomes

b

b

Mortality at 3 mo, %

Abbreviations: DOAC 5 direct oral anticoagulant; FFP 5 fresh frozen plasma; ICH 5 intracerebral hemorrhage; IQR 5
interquartile range; mRS 5 modified Rankin Scale; NIHSS 5 NIH Stroke Scale; PCC 5 prothrombin complex concentrates;
VKA 5 vitamin K antagonist.
a
Defined as mRS score of .2.
b
One patient lost to follow-up.
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Figure 1

Horizontal “Grotta” bars

Distribution of modified Rankin Scale scores at 3 months in patients with intracerebral hemorrhage pretreated with direct
oral anticoagulants (DOACs) or vitamin K antagonists (VKAs).

prevalence of chronic kidney disease in VKApretreated patients (21.9% vs 6.5%, p 5 0.020).
No differences were found in the baseline laboratory
parameters except for higher INR (2.9 6 1.14 vs 1.6
6 0.72, p , 0.001) and activated partial thromboplastin time (40.3 6 11.2 vs 34.8 6 6.1, p 5
0.002) values found as expected in patients with
VKA- compared to DOAC-related ICH (table 1).
Patients with DOAC-related ICH had lower median
NIHSSadm scores (8 [IQR 3–14] vs 15 [IQR 7–25]
points, p 5 0.003), higher median admission Glasgow Coma Scale scores (14 [IQR 12–15] vs 13 [IQR
7–15] points, p 5 0.008), and lower baseline
median ICH volume (12.8 [IQR 4–40] vs 24.3
[IQR 11–58.8] cm3, p 5 0.007). Moreover, baseline
ICH volume .30 cm3 was less prevalent in DOACrelated ICH (25.5% vs 45.6%, p 5 0.018). The
median ICH score was also lower in DOACrelated ICH (1 [IQR 0–2] vs 2 [IQR 1–3] points,
p 5 0.049), while severe ICH (ICH score .2) was
less prevalent in DOAC-related ICH (17% vs
36.8%, p 5 0.013).
Pharmacologic interventions during hospitalization, including the administration of fresh-frozen
plasma, prothrombin complex concentrates, and vitamin K, were more common (p , 0.01) in patients
with VKA- compared to those with DOAC-related
ICH. However, no differences were detected in the
rate of invasive procedures (intubation, surgical
decompression, or external ventricular drainage)
between the 2 groups during hospitalization (table 2).
1146
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One patient pretreated with dabigatran received treatment with idarucizumab.
The 2 groups did not differ in neuroimaging parameters at 24 hours except for cerebral edema and
midline shift, which were less prevalent in DOACrelated ICH (53.2% vs 71.0%, p 5 0.030; and
26.1% vs 45.6%, p 5 0.022). Moreover, the rates
of hematoma expansion (23.1% vs 37.1%, p 5
0.116) and ICH volume .30 cm3 at 24 hours
(42.5% vs 56.1%, p 5 0.117) tended to be lower
in patients with DOAC-related ICH. Patients with
DOAC-related ICH had lower median NIHSS scores
at 24 hours (6 [IQR 2–15] vs 15 [IQR 6–23] points,
p 5 0.007) and at hospital discharge (3 [IQR 1–10]
vs 6 [IQR 3.5–15] points, p 5 0.011). They also
presented with lower median mRS scores at discharge
(3 [IQR 1–5] vs 4 [IQR 3–6] points, p 5 0.002) and
at 3 months (3 [IQR 0–5] vs 4 [IQR 3–6] points, p 5
0.001). In addition, patients with DOAC-related
ICH had lower disability (mRS score .2) rates at
3 months (51.1% vs 76.3%, p 5 0.002) and greater
3-month functional improvement (shift analysis in
mRS scores) compared to VKA-related ICH (p ,
0.001 by Cochran-Mantel-Haenszel test; figure 1).
The 2 groups did not differ in terms of in-hospital
(21.2% vs 33.3%, p for log-rank test 5 0.128) and
3-month (21.7% vs 36.3%, p for log-rank test 5
0.092; figure e-1) mortality rates.
In univariable and multivariable regression analyses, DOAC-related ICH was independently associated with lower baseline hematoma volume
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Table 3

Simple and multiple linear regression analyses evaluating the association of baseline characteristics
with cube root of hematoma volume on hospital admission
Simple linear regression

Multiple linear regression

Linear regression
coefficient (95% CI)

p

Linear regression
coefficient (95% CI)

p

Age

0.002 (20.02 to 0.021)

0.863

—

—

Male

20.093 (20.473 to 0.286)

0.628

—

—

BMI

0.007 (20.025 to 0.039)

0.670

—

—

CHA2DS2-VASc score

0.088 (20.024 to 0.200)

0.123

—

—

HAS-BLED score

0.239 (0.069 to 0.409)

0.006

0.212 (0.031 to 0.393)

0.022

Hypertension

0.125 (20.692 to 0.942)

0.764

—

—

Diabetes mellitus

0.060 (20.320 to 0.440)

0.756

—

—

Hyperlipidemia

20.190 (20.567 to 0.186)

0.320

—

—

Heart failure

20.088 (20.530 to 0.354)

0.694

—

—

Current smoking

0.213 (20.414 to 0.840)

0.503

—

—

Coronary artery disease

0.335 (20.056 to 0.725)

0.103

—

—

Kidney failure

20.008 (20.504 to 0.488)

0.975

—

—

History of ischemic stroke

0.150 (20.236 to 0.536)

0.445

—

—

History of ICH

20.509 (21.282 to 0.265)

0.196

—

—

Statin pretreatment

20.120 (20.510 to 0.271)

0.545

—

—

Antiplatelet pretreatment

0.618 (0.221 to 1.014)

0.002

0.462 (0.068 to 0.855)

0.022

Dual antiplatelet pretreatment

20.133 (20.961 to 0.695)

0.751

—

—

DOAC pretreatment

20.571 (20.974 to 20.168)

0.006

20.569 (20.974 to 20.163)

0.006

Admission SBP

0.004 (20.002 to 0.010)

0.199

—

—

Admission DBP

0.009 (20.001 to 0.018)

0.084

0.010 (0.001 to 0.020)

0.035

Abbreviations: BMI 5 body mass index; CI 5 confidence interval; DBP 5 diastolic blood pressure; DOAC 5 direct oral
anticoagulant; ICH 5 intracerebral hemorrhage; NIHSS 5 NIH Stroke Scale; SBP 5 systolic blood pressure.

(linear regression coefficient 5 20.569, 95% confidence interval [CI] 20.97 to 20.163, p 5 0.006;
table 3), lower NIHSSadm score (linear regression
coefficient 5 20.409, 95% CI 20.759 to 20.059,
p 5 0.022; table e-1), and lower likelihood of
severe ICH on admission (OR 5 0.34, 95% CI
0.13–0.87, p 5 0.025; table e-2). Moreover,
DOAC-related ICH tended to be associated with
lower likelihood of baseline hematoma volume of
.30 cm3 on admission CT scan in multivariable
logistic regression models adjusted for potential
confounders (OR 5 0.46, 95% CI 0.20–1.05,
p 5 0.067; table e-3). Even though DOACrelated ICH was associated with lower odds of
3-month disability (OR 5 0.32, 95% CI 0.16–
0.66, p 5 0.002; table e-4) and greater likelihood
of 3-month functional improvement (common OR
5 3.03, 95% CI 1.58–5.88, p 5 0.001; table e-5)
in initial univariable analyses, these associations did
not retain their statistical significance in multivariable models adjusted for baseline hematoma volume, NIHSSadm score, and ICH score (OR 5
0.77, 95% CI 0.29–2.04, p 5 0.602; common

OR 5 1.44, 95% CI 0.69–3.03, p 5 0.324; tables
e-4 and e-5, respectively).
Because of the presence of collinearity regarding
the history of DOAC pretreatment with both NIHSSadm score (table e-1) and baseline ICH volume (table
1), we performed additional univariable and multivariable logistic and ordinal regression analyses on the
association of DOAC pretreatment with disability
and functional improvement after excluding these 2
variables from the multivariable models. In the final
multivariable analyses, DOAC-related ICH was associated with lower odds of 3-month disability (OR 5
0.45, 95% CI 0.20–0.99, p 5 0.049; table e-6) and
greater likelihood of 3-month functional improvement (common OR 5 3.12, 95% CI 1.64–6.25,
p 5 0.001; table e-7).
Meta-analysis of observational studies. A MEDLINE

and SCOPUS database search yielded 460 and 328
results, respectively. After duplicates were removed,
the titles and abstracts from the remaining 768 studies were screened, and 7 potentially eligible studies for
the meta-analysis were retained. After retrieval of the
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Figure 2

Pairwise meta-analyses of eligible observational studies

Forest plots of the association between direct oral anticoagulant (DOAC)–related intracerebral hemorrhage (ICH) and (A) admission hematoma volumes, (B)
in-hospital mortality rates, and (C) hematoma expansion at 24 hours in a pairwise meta-analysis. Comparison group consisted of patients with vitamin K
antagonists (VKA)–related ICH. CI 5 confidence interval; IV 5 inverse variance; M-HV 5 Mantel-Haenszel variance.

full-text version of the aforementioned 7 studies, 4
studies were excluded (table e-8). In the final presentation of the literature search results, there was no
conflict or disagreement between the 3 reviewers who
performed the literature search, and the 3 studies that
met the inclusion criteria,21,23,24 together with the
data from the present report, were included in both
the qualitative and quantitative syntheses (figure e-2).
The characteristics and bias assessment of the
included studies (363 total patients with ICH, mean
age 76.6 years, men 56.8%) are shown in table e-9.
In the pooled analysis, DOAC-related ICH was
associated with lower baseline hematoma volumes
on admission CT (standardized mean difference 5
20.57, 95% CI 21.02 to 20.12, p 5 0.010; figure
2A) and lower in-hospital mortality rates (OR 5
0.44, 95% CI 0.21–0.91, p 5 0.030; figure 2B).
The association of DOAC-related ICH with hematoma expansion at 24 hours was marginally not
achieved (OR 5 0.47, 95% CI 0.22–1.04, p 5
0.06; figure 2C). In all aforementioned analyses, no
evidence of heterogeneity was present (p for Cochran
1148
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Q . 0.1 and I 2 , 55%), while it should also be
noted that hematoma expansion definition was univocal in all included studies.21,23,24
The results of this cross-sectional
study suggest that DOAC-related ICH has a more
favorable neuroimaging and clinical profile on hospital admission compared to VKA-related ICH. More
specifically, DOAC-related ICH is associated with
lower baseline hematoma volumes, NIHSSadm scores,
and ICH scores in multivariable analyses adjusted for
numerous potential confounders.
After our results were pooled with the available literature, our pairwise meta-analysis documented
a lower in-hospital mortality rate in patients with
DOAC-related ICHs. This observation contradicts
the findings of both the Randomized Evaluation of
Long-Term Anticoagulation Therapy (RE-LY)25 and
Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial
Fibrillation (ROCKET AF) trials,26 which have
DISCUSSION
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suggested a similar 30-day case fatality risk for
DOAC-related and VKA-related ICHs.6 However,
our findings are in accordance with the results of
a recent study reporting lower mortality rates in
DOAC-treated compared to VKA-treated patients
with traumatic ICH.27 Potential differences in baseline characteristics and in management of patients
with ICH during hospitalization may account for
these discrepant findings between observational studies and randomized controlled trials. In addition,
a marginally nonsignificant lower rate of hematoma
expansion (OR 5 0.47, 95% CI 0.22–1.04, p 5
0.06) was recorded in the pairwise meta-analysis of
available studies reporting radiologic outcomes in patients with both DOAC- and VKA-related ICH. This
finding is intriguing and deserves further investigation because the pooled prevalence of hematoma
expansion reported in all available studies on
DOAC-related ICH (17.9%, 95% CI 8.4–34.2;
table e-10 and figure e-3) appears to be lower than
the respective rates of hematoma expansion reported
in previous 3 large studies evaluating patients with
VKA-related ICH (36.0%, 50.0%, and 53.8%).9,28,29
The difference in baseline hematoma volume reported between DOAC- and VKA-related ICHs,
which has already been observed and replicated in
animal models,30 could be partially attributed to the
different pharmacologic properties between the 2 oral
anticoagulation classes.21,23,24 DOACs not only have
a shorter half-life than VKAs but also selectively
inhibit thrombin (dabigatran) or factor Xa (apixaban,
rivaroxaban) and thus have no effect on the extrinsic
coagulation pathway and the subsequent prothrombin formation and platelet aggregation, in contrast to
VKAs.31 Another potential explanation for the larger
hematoma volume observed in VKA-related ICHs
could be the higher risk of both cerebral microbleed
(CMB) presence32,33 and CMB progression34 in
stroke patients on VKA treatment, especially in those
with higher CHA2DS2-VASc scores, increased prothrombin time,32 and INR variability.33 Because this
increase in CMB number has not yet been evident in
DOAC-treated patients,35 the hypothesis of ICH
incidence between DOAC- and VKA- treated patients according to CMB progression will be further
tested within the setting of the Cerebral Microbleeds
During the Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients With
Nonvalvular Atrial Fibrillation (CMB-NOW) study
(NCT02356432).36
Even though the present report is one of the largest prospective, international, cross-sectional studies
to date comparing clinical and radiologic outcomes
in patients with DOAC- and VKA-related ICH (table
e-9), several limitations should be acknowledged.
First, as per the study protocol, no screening log

was kept during the recruitment period of the study,
and all eligible patients satisfying the predefined
inclusion criteria were directly recruited after initial
assessment in each participating institution. Second,
patients in the 2 groups were not randomized to
DOAC or VKA administration; thus, imbalances in
both baseline characteristics and other potential confounders could be present. Third, evaluation of premorbid mRS scores was not included in our study
protocol. Thus, we cannot provide exact estimates
of patients’ functional status before the index event.
However, it should be noted that the percentages of
included patients with history of any stroke, ischemic
stroke, or ICH before the index event were equally
distributed between the DOAC- and VKA-treated
groups (table 1). Moreover, because onset-toneuroimaging time was not prospectively recorded,
potential imbalances in the 2 groups could be present
(despite the fact that all patients underwent baseline
neuroimaging studies within 24 hours). On the other
hand, it should be kept in mind that we detected no
differences in baseline characteristics among patients
with DOAC- and VKA-related ICH, except for those
related directly to the mechanism of anticoagulation
(INR, activated partial thromboplastin time values)
and the rates of chronic kidney disease history.
Despite the reported higher rates of chronic kidney
disease in the VKA-related ICH group, no significant
differences in the admission creatinine clearance values were documented between the 2 groups.
Fourth, even though patients with VKA-related
ICH had higher rates of antiplatelet pretreatment history compared to patients with DOAC-related ICH
(38.5% vs 27.3%), this difference was not statistically
significant (p 5 0.187), while the history of prior
antiplatelet intake was incorporated in all univariable/multivariable analyses. Fifth, no subgroup analyses according to DOAC type were feasible because of
the low number of patients included in each of the
3 DOAC subgroups. This analysis may be clinically
relevant because distinct bleeding patterns and bleeding risks have been reported in different DOACs.2,37
Sixth, there was no central adjudication of both clinical or imaging outcomes. However, all radiologic
parameters were evaluated in the participating institutions by neuroradiologists blinded to the patients’
clinical information. Seventh, we did not systematically evaluate patients with MRI on hospital admission for the detection of CMBs; thus, a possible
moderating effect of CMB count on the reported
associations remains uncertain.10 Finally, even though
we detected no significant differences between patients with DOAC- and VKA-related ICH on the
rates of hematoma expansion and in-hospital and
3-month mortality rates, when our data were coupled
in pooled analyses with available literature data, the
Neurology 89

September 12, 2017

1149

ª 2017 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

differences between patients with DOAC- and VKArelated ICH were significant for in-hospital mortality
rates (p 5 0.03) with a tendency (p 5 0.06) for less
hematoma expansion. This observation underlines
the fact that even though our multicenter observational study managed to include a high number of
patients with DOAC- and VKA-related ICHs, it is
presumably still underpowered to detect significant
differences in some of the clinical outcomes between
the 2 groups. This highlights the need for additional
adequately powered and properly designed studies on
the topic. We believe that both our observational
study data and the pooled estimates from the metaanalysis could provide invaluable insight for future
power calculations and sample size estimations.
The present multicenter cross-sectional study suggests that DOAC-related ICHs appear to have more
favorable neuroimaging and clinical profiles on hospital admission compared to VKA-related ICH. These
findings underscore DOACs as an attractive therapeutic option in terms of risk of severe ICH in patients with NVAF and high risk of intracranial
bleeding. This observation requires independent confirmation in larger prospective cohort studies, which
will further evaluate comparatively ICH severity and
provide robust estimates of cumulative ICH incidence rates between DOAC- and VKA-treated
patients.
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